Aurinia Q3 revenue $14.7M (+122% QoQ); net loss $50.3M; LUPKYNIS PSF conversion >68%

Aurinia Pharmaceuticals Inc.

2021-Q3 EPS reported -$1.15 revenue$22,201,000

Net revenue $14.7M vs $29K in Q3 2020; net loss $50.3M ($0.39 per share) vs $42.1M loss a year ago.
Cash and investments $286.4M; 2021 revenue guidance maintained at $40-50M.
LUPKYNIS PSFs totaled 412 in Q3; cumulative >1,265; conversion rate improved to >68% from 50% in Q2.
Payer coverage confirmed for 87% of total lives; two preclinical assets AUR200 and AUR300 added.
AURORA 2 final results expected by end of 2021; Swiss MAA filed; EMA decision anticipated Q3 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.